![Peter Anastasiou](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Anastasiou
Chief Operating Officer at
HARMONY BIOSCIENCES HOLDINGS, INC.
Net worth: - $ as of 2026-05-30
Profile
Peter E.
Anastasiou is currently Director at Pharmaceutical Research & Manufacturers of America since 2017.
Mr. Anastasiou is also Chief Operating Officer & Senior Executive VP at Harmony Biosciences Holdings, Inc. starting in 2023.
Formerly, Mr. Anastasiou was Chief Executive Officer & Director at Capsida Biotherapeutics, Inc. from 2022 to 2025.
Other former roles include Marketing Director at Bristol Myers Squibb Co., Principal at Eli Lilly & Co., Executive Vice President-North America at H.
Lundbeck A from 2009 to 2021, Vice President-Marketing at Neuronetics, Inc., and President at Lundbeck Seattle BioPharmaceuticals, Inc. Education includes an undergraduate degree from Albion College and an MBA from Kelley School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-01 | 0 ( -.--% ) | - $ | 2026-05-30 |
Peter Anastasiou active positions
| Companies | Position | Start |
|---|---|---|
| HARMONY BIOSCIENCES HOLDINGS, INC. | Chief Operating Officer | 2026-04-01 |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Director/Board Member | 2017-06-30 |
Former positions of Peter Anastasiou
| Companies | Position | End |
|---|---|---|
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Chief Executive Officer | 2025-09-30 |
| H. LUNDBECK A/S | Corporate Officer/Principal | 2021-12-30 |
| ALDER BIOPHARMACEUTICALS, INC. | President | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | - |
Training of Peter Anastasiou
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
64
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
H. Lundbeck A/S
 H. Lundbeck A/S Pharmaceuticals: MajorHealth Technology Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases | Health Technology |
Neuronetics, Inc.
 Neuronetics, Inc. Medical SpecialtiesHealth Technology Develops and commercializes non-invasive therapies for psychiatric and neurological disorders | Health Technology |
Albion College
 Albion College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harmony Biosciences Holdings, Inc.
 Harmony Biosciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for patients living with rare neurological disorders | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Health Technology |
- Stock Market
- Insiders
- Peter Anastasiou
